aDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif
bCoordination Center for Cancer Screening, Bretonneau 2 University Hospital, Tours
cKantar Health, Montrouge
dDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon
eLéon Bérard Cancer Centre, Lyon
fPorte de Saint-Cloud Clinic, Boulogne-Billancourt
gRoche, Boulogne Billancourt
hDepartment of Cancer Control, Paoli-Calmettes Institute
iAix Marseille University, UMR_S912, IRD
jINSERM, UMR912 (SESSTIM), Marseille, France
Correspondence to Jean-François Morère, MD, PhD, Department of Oncology and Hematology, Paul-Brousse University Hospital, 12 Avenue Paul Vaillant Couturier, 94800 Villejuif, France Tel: +33 0 145 59 36 30; fax: +33 0 145 59 34 98; e-mail: [email protected]
Received February 16, 2015
Accepted February 18, 2015